Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia

Author: Al-Riyami Arwa Z.  

Publisher: Informa Healthcare

ISSN: 1042-8194

Source: Leukemia and Lymphoma, Vol.54, Iss.8, 2013-08, pp. : 1788-1790

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content